Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176288 | 0.80 | MAPK8 (0.39) | MEN1ALDH1A1KMT2AMAPTMAPK8 | |
| SCHEMBL25446307 | 0.80 | NT5E (0.38) | MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL25444963 | 0.76 | MEN1 (0.34) | MEN1ALDH1A1KMT2AMAPK8 | |
| SCHEMBL13106482 | 0.74 | MAPK8 (0.41) | MAPTPDPK1JAK2DNM1SMN1; SMN2 | |
| SCHEMBL25446131 | 0.72 | MAPT (0.35) | MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL24858683 | 0.70 | MAPK1 (0.37) | KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL25444966 | 0.70 | GAA (0.41) | MEN1KMT2A | |
| SCHEMBL24858305 | 0.68 | CCNB2 (0.31) | — | |
| SCHEMBL24858675 | 0.68 | NPC1 (0.33) | — | |
| SCHEMBL25062019 | 0.67 | MEN1 (0.36) | MEN1ALDH1A1KMT2AMAPTJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-08-13 | — | — | US | disclosed |
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | MEN1 3869/4885ALDH1A1 1046/4885KMT2A 3295/4885 |
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | BRCA1, ESR2, ESR1 | MEN1 4136/4885ALDH1A1 608/4885KMT2A 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.